Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMTIP9S)

• Drug Name: YH008 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Aggressive cancer	2A00-2F9Z	Investigative	[1]

• Cross-matching ID: TTD Drug ID: DMTIP9S

Molecule-Related Drug Atlas

Drug(s) Targeting CD40L receptor (CD40)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BI 655064	DMF86P2	Lupus	4A40	Phase 2	[2]
APX005M	DMX2P5G	Melanoma	2C30	Phase 2	[3]
ASKP-1240	DM1CLKO	Transplant rejection	NE84	Phase 2	[4]
CFZ533	DM1TWIE	Graves disease	5A02.0	Phase 2	[2]
Dazodalibep	DM7YII9	Kidney transplant rejection	NE84	Phase 2	[5]
Iscalimab	DMW4CR8	Type-1 diabetes	5A10	Phase 2	[6]
KPL-404	DMQJODL	Rheumatoid arthritis	FA20	Phase 2	[7]
AT-1501	DMQIA5K	Amyotrophic lateral sclerosis	8B60.0	Phase 2	[8]
Frexalimab	DMMJTYP	Multiple sclerosis	8A40	Phase 2	[9]
SL-172154	DMN3D72	Ovarian cancer	2C73	Phase 1	[10]

Drug(s) Targeting Programmed cell death protein 1 (PD-1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Nivolumab	DMAB9QE	Melanoma	2C30	Approved	[11]
Tislelizumab	DMGVUO5	Hodgkin lymphoma	2B30	Approved	[12]
MK-3475	DMBYNW0	Melanoma	2C30	Approved	[11]
Pembrolizumab	DMFQEA6	Melanoma	2C30	Approved	[13]
Cemiplimab	DMKMJHE	Cutaneous squamous cell carcinoma	2C30	Approved	[14]
Retifanlimab	DMRKTCP	Neuroendocrine cancer	2B72.1	Approved	[3]
Sintilimab	DMGWR0C	Hodgkin lymphoma	2B30	Approved	[15]
Dostarlimab	DM78NWP	Endometrial cancer	2C76	Approved	[16]
Toripalimab	DMSGA6Z	Demodex blepharitis	1G07	Approved in China	[17]
PDR001	DM53J6B	Melanoma	2C30	Phase 3	[18]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
CD40L receptor (CD40)	TTN6Y9A	TNR5_HUMAN	Not Available	[1]
Programmed cell death protein 1 (PD-1)	TTNBFWK	PDCD1_HUMAN	Not Available	[1]

References

• [1] Clinical pipeline report, company report or official report of Biocytogen
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1874).
• [5] The enhanced immunopharmacology of VIB4920, a novel Tn3 fusion protein and CD40L antagonist, and assessment of its safety profile in cynomolgus monkeys. Br J Pharmacol. 2020 Mar;177(5):1061-1076.
• [6] Developments in immunosuppression. Curr Opin Organ Transplant. 2021 Feb 1;26(1):91-96.
• [7] Anti-CD40 antibody KPL-404 inhibits T cell-mediated activation of B cells from healthy donors and autoimmune patients. Arthritis Res Ther. 2021 Jan 6;23(1):5.
• [8] ClinicalTrials.gov (NCT04322149) A Phase 2a Open-Label, Multi-Center Study to Evaluate the Safety and Tolerability of Multiple Doses of AT-1501 in Adults With ALS. U.S.National Institutes of Health.
• [9] ClinicalTrials.gov (NCT04879628) A Phase 2, Double-blind, Randomized, Placebo-controlled Study Assessing Efficacy and Safety of SAR441344, a CD40L-antagonist Monoclonal Antibody, in Participants With Relapsing Multiple Sclerosis. U.S.National Institutes of Health.
• [10] Clinical pipeline report, company report or official report of Shattuck Labs.
• [11] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [12] Tislelizumab: an investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC). Expert Opin Investig Drugs. 2020 Dec;29(12):1355-1364.
• [13] Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730.
• [14] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [15] Sintilimab: First Global Approval. Drugs. 2019 Feb;79(3):341-346.
• [16] Dostarlimab in the treatment of recurrent or primary advanced endometrial cancer. Future Oncol. 2021 Mar;17(8):877-892.
• [17] Toripalimab: the First Domestic Anti-Tumor PD-1 Antibody in China. Front Immunol. 2022 Jan 12;12:730666.
• [18] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)